{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:42:39Z","timestamp":1791290559837,"version":"4.3.0"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108294","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:36:19Z","timestamp":1781246179000},"page":"108294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting tumor\u2011associated macrophages in osteosarcoma: From molecular reprogramming to immuno-regenerative scaffolds"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-2938","authenticated-orcid":false,"given":"Zhi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.phrs.2026.108294_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143503","article-title":"Origin and therapies of osteosarcoma","volume":"14","author":"Moukengue","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12938-021-00860-0","article-title":"Osteosarcoma: a review of current and future therapeutic approaches","volume":"20","author":"Zhao","year":"2021","journal-title":"Biomed. Eng. Online"},{"issue":"11","key":"10.1016\/j.phrs.2026.108294_bib3","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/cncr.34163","article-title":"Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017","volume":"128","author":"Cole","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2026.108294_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11912-021-01053-7","article-title":"Update on Osteosarcoma","volume":"23","author":"Belayneh","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"12","key":"10.1016\/j.phrs.2026.108294_bib5","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2026.108294_bib6","article-title":"Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post-Operative Osteosarcoma Treatment","author":"Dong","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.phrs.2026.108294_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.116110","article-title":"LIPA-driven reprogramming of tumor-associated macrophages shapes an immunosuppressive microenvironment in osteosarcoma","volume":"171","author":"Guo","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2026.108294_bib8","article-title":"Osteosarcoma Cell-Derived Exosomal ELFN1-AS1 Mediates Macrophage M2 Polarization via Sponging miR-138-5p and miR-1291 to Promote the Tumorgenesis of Osteosarcoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108294_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41419-024-06487-y","article-title":"Pivotal role of IL-8 derived from the interaction between osteosarcoma and tumor-associated macrophages in osteosarcoma growth and metastasis via the FAK pathway","volume":"15","author":"Tatsuno","year":"2024","journal-title":"Cell. Death Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00109-018-1711-0","article-title":"Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1","volume":"97","author":"Su","year":"2019","journal-title":"J. Mol. Med. (Berl. )"},{"key":"10.1016\/j.phrs.2026.108294_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.217388","article-title":"Nano-\/nanobio-technology-enhanced CAR-T cell therapy: engineering the next generation of immunotherapies","volume":"550","author":"Zuo","year":"2026","journal-title":"Coord. Chem. Rev."},{"issue":"8","key":"10.1016\/j.phrs.2026.108294_bib12","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.7150\/thno.125686","article-title":"Sono-piezoelectric cues regulate neuroinflammatory reflex-arc-mediated \u03b17nAChR-P2RX7 axis to dampen osteoarthritis-correlated pain with osteoarthritis attenuation","volume":"16","author":"Zhong","year":"2026","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.phrs.2026.108294_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202516305","article-title":"Dual-Heterojunctions with Reversibly Photoactivated Structure Shift Alternately Decode Photocatalytic H(2) Burst and Cascade Catalytic ROS Birth to Repress Cancer","volume":"38","author":"Wang","year":"2026","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.phrs.2026.108294_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202512230","article-title":"Multichannel Immune Nanoregulators Suppress Lactic Acid Metabolism and Lactic Acid-Shaped Acidic Microenvironment to Uproot Anti-Tumor Immunosuppression","volume":"38","author":"Fang","year":"2026","journal-title":"Adv. Mater."},{"issue":"15","key":"10.1016\/j.phrs.2026.108294_bib15","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.7150\/thno.113887","article-title":"GD2-mediated impairment of macrophage phagocytosis drives pulmonary metastasis in osteosarcoma","volume":"15","author":"He","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2026.108294_bib16","first-page":"248","article-title":"Engineered macrophage nanoparticles enhance microwave ablation efficacy in osteosarcoma via targeting the CD47-SIRP\u03b1 Axis: A novel Biomimetic immunotherapeutic approach","volume":"47","author":"Ji","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.phrs.2026.108294_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.actbio.2024.12.048","article-title":"Osteosarcoma-targeting Pt(IV) prodrug amphiphile for enhanced chemo-immunotherapy via Ca(2+) trapping","volume":"193","author":"Yan","year":"2025","journal-title":"Acta Biomater."},{"issue":"34","key":"10.1016\/j.phrs.2026.108294_bib18","doi-asserted-by":"crossref","first-page":"30786","DOI":"10.1021\/acsnano.5c00223","article-title":"Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal-Photodynamic-Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells","volume":"19","author":"Pan","year":"2025","journal-title":"ACS Nano"},{"issue":"51","key":"10.1016\/j.phrs.2026.108294_bib19","article-title":"KERS-Inspired Nanostructured Mineral Coatings Boost IFN-\u03b3 mRNA Therapeutic Index for Antitumor Immunotherapy","volume":"35","author":"Shao","year":"2023","journal-title":"Adv. Mater."},{"issue":"7","key":"10.1016\/j.phrs.2026.108294_bib20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/2326-6066.CIR-16-0259","article-title":"All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108294_bib21","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/ptr.8146","article-title":"Cucurbitacin B modulates M2 macrophage differentiation and attenuates osteosarcoma progression via PI3K\/AKT pathway","volume":"38","author":"Wu","year":"2024","journal-title":"Phytother. Res."},{"issue":"29","key":"10.1016\/j.phrs.2026.108294_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202309038","article-title":"ZIF-8-Encapsulated Pexidartinib Delivery via Targeted Peptide-Modified M1 Macrophages Attenuates MDSC-Mediated Immunosuppression in Osteosarcoma","volume":"20","author":"Dong","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.phrs.2026.108294_bib23","first-page":"83","article-title":"TME-responsive nanocomposite hydrogel with targeted capacity for enhanced synergistic chemoimmunotherapy of MYC-amplified osteosarcoma","volume":"47","author":"Ma","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.phrs.2026.108294_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.actbio.2023.08.046","article-title":"Aspect ratio-dependent dual-regulation of the tumor immune microenvironment against osteosarcoma by hydroxyapatite nanoparticles","volume":"170","author":"Wu","year":"2023","journal-title":"Acta Biomater."},{"issue":"34","key":"10.1016\/j.phrs.2026.108294_bib25","article-title":"Time-Sequential and Multi-Functional 3D Printed MgO(2)\/PLGA Scaffold Developed as a Novel Biodegradable and Bioactive Bone Substitute for Challenging Postsurgical Osteosarcoma Treatment","volume":"36","author":"Li","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.phrs.2026.108294_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.884196","article-title":"A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells","volume":"12","author":"Thaker","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1824323","article-title":"Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRP\u03b1 \"don't eat me\" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation","volume":"9","author":"Hendriks","year":"2020","journal-title":"Oncoimmunology"},{"issue":"24","key":"10.1016\/j.phrs.2026.108294_bib28","article-title":"Biomimetic Nano-Degrader Based CD47-SIRP\u03b1 Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair","volume":"11","author":"Gao","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"31","key":"10.1016\/j.phrs.2026.108294_bib29","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.phrs.2026.108294_bib30","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108294_bib31","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.phrs.2026.108294_bib32","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1182\/bloodadvances.2024013338","article-title":"Magrolimab plus rituximab with or without chemotherapy in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"8","author":"Maakaron","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2026.108294_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1518787","article-title":"Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy","volume":"16","author":"Krishnamoorthy","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-025-01742-x","article-title":"HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRP\u03b1 pathway with high safety and preclinical efficacy for hematological and solid tumors","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108294_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20507","article-title":"Don't eat me\/eat me signals as a novel strategy in cancer immunotherapy","volume":"9","author":"Khalaji","year":"2023","journal-title":"Heliyon"},{"issue":"7","key":"10.1016\/j.phrs.2026.108294_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cac2.12579","article-title":"\"Find Me\" and \"Eat Me\" signals: tools to drive phagocytic processes for modulating antitumor immunity","volume":"44","author":"Xiao","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.phrs.2026.108294_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2023.01.038","article-title":"A nanodrug combining CD47 and sonodynamic therapy efficiently inhibits osteosarcoma deterioration","volume":"355","author":"Gong","year":"2023","journal-title":"J. Control. Release"},{"issue":"47","key":"10.1016\/j.phrs.2026.108294_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202003214","article-title":"Recent Advances in Nanomaterial-Assisted Combinational Sonodynamic Cancer Therapy","volume":"32","author":"Liang","year":"2020","journal-title":"Adv. Mater."},{"issue":"11","key":"10.1016\/j.phrs.2026.108294_bib39","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1039\/C9CS00648F","article-title":"Multifunctional sonosensitizers in sonodynamic cancer therapy","volume":"49","author":"Son","year":"2020","journal-title":"Chem. Soc. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2026.108294_bib40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.32604\/or.2023.030767","article-title":"Codelivery of anti-CD47 antibody and chlorin e6 using a dual pH-sensitive nanodrug for photodynamic immunotherapy of osteosarcoma","volume":"32","author":"Xiao","year":"2024","journal-title":"Oncol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108294_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41419-018-1285-3","article-title":"Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma","volume":"10","author":"Mohanty","year":"2019","journal-title":"Cell. Death Dis."},{"issue":"10","key":"10.1016\/j.phrs.2026.108294_bib42","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/1878-0261.12556","article-title":"Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on","volume":"13","author":"Mohanty","year":"2019","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13018-024-04950-2","article-title":"Modulating tumor-associated macrophage polarization by anti-maRCO mAb exerts anti-osteosarcoma effects through regulating osteosarcoma cell proliferation, migration and apoptosis","volume":"19","author":"Ding","year":"2024","journal-title":"J. Orthop. Surg. Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108294_bib44","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.immuni.2025.04.017","article-title":"Complex neural-immune interactions shape glioma immunotherapy","volume":"58","author":"Song","year":"2025","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1186\/s12967-025-06523-1","article-title":"Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory\/relapsed gliomas","volume":"23","author":"Gu","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108294_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","article-title":"Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma","volume":"31","author":"Quintarelli","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib47","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11033-023-09201-x","article-title":"The application of MARCO for immune regulation and treatment","volume":"51","author":"Zhou","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"9","key":"10.1016\/j.phrs.2026.108294_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9091129","article-title":"MARCO(+) Macrophage Dynamics in Regenerating Liver after 70% Liver Resection in Mice","volume":"9","author":"Elchaninov","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2026.108294_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1790067","article-title":"The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights","volume":"17","author":"Ge","year":"2026","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108294_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008744","article-title":"Targeting refractory\/recurrent neuroblastoma and osteosarcoma with anti-CD3\u00d7anti-GD2 bispecific antibody armed T cells","volume":"12","author":"Yankelevich","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108294_bib51","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.apsb.2024.12.018","article-title":"Disrupting calcium homeostasis and glycometabolism in engineered lipid-based pharmaceuticals propel cancer immunogenic death","volume":"15","author":"Peng","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2026.108294_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123087","article-title":"Nanomedicine-unlocked radiofrequency dynamic therapy dampens incomplete radiofrequency ablation-arised immunosuppression to suppress cancer relapse","volume":"317","author":"Fang","year":"2025","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib53","article-title":"Camouflaged membrane-bridged radionuclide\/Mn single-atom enzymes target lipid metabolism disruption to evoke antitumor immunity","volume":"12","author":"Yang","year":"2025","journal-title":"Mil. Med. Res."},{"issue":"23","key":"10.1016\/j.phrs.2026.108294_bib54","article-title":"Enhanced Osteosarcoma Immunotherapy via CaCO(3) Nanoparticles: Remodeling Tumor Acidic and Immune Microenvironment for Photodynamic Therapy","volume":"13","author":"Gao","year":"2024","journal-title":"Adv. Healthc. Mater."},{"issue":"8","key":"10.1016\/j.phrs.2026.108294_bib55","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1039\/D2BM01900K","article-title":"Biodegradable photothermal thermosensitive hydrogels treat osteosarcoma by reprogramming macrophages","volume":"11","author":"Luo","year":"2023","journal-title":"Biomater. Sci."},{"issue":"22","key":"10.1016\/j.phrs.2026.108294_bib56","article-title":"Bioinspired Tumor-Targeting and Biomarker-Activatable Cell-Material Interfacing System Enhances Osteosarcoma Treatment via Biomineralization","volume":"10","author":"Yang","year":"2023","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.phrs.2026.108294_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122059","article-title":"The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis","volume":"296","author":"Jia","year":"2023","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.phrs.2026.108294_bib58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"38","key":"10.1016\/j.phrs.2026.108294_bib59","doi-asserted-by":"crossref","first-page":"44689","DOI":"10.1021\/acsami.3c07379","article-title":"Cancer-Erythrocyte Membrane-Mimicking Fe(3)O(4) Nanoparticles and DHJS for Ferroptosis\/Immunotherapy Synergism in Tumors","volume":"15","author":"Yu","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"Pt 2","key":"10.1016\/j.phrs.2026.108294_bib60","article-title":"Cu-Tremella fuciformis polysaccharide-based tumor microenvironment-responsive injectable gels for cuproptosis-based synergistic osteosarcoma therapy","volume":"270","author":"Xie","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"13","key":"10.1016\/j.phrs.2026.108294_bib61","article-title":"Immunogenic Cell Death in Hematological Malignancy Therapy","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"12","key":"10.1016\/j.phrs.2026.108294_bib62","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2026.108294_bib63","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"7","key":"10.1016\/j.phrs.2026.108294_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012269","article-title":"Enhanced antitumor immunity of VNP20009-CCL2-CXCL9 via the cGAS\/STING axis in osteosarcoma lung metastasis","volume":"13","author":"Liu","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108294_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010511","article-title":"Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors","volume":"13","author":"Luke","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2026.108294_bib66","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3389\/fimmu.2020.01210","article-title":"Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview","volume":"11","author":"Romerio","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108294_bib67","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1021\/acs.molpharmaceut.8b00691","article-title":"TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings","volume":"15","author":"Shetab Boushehri","year":"2018","journal-title":"Mol. Pharm."},{"issue":"9580","key":"10.1016\/j.phrs.2026.108294_bib68","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.phrs.2026.108294_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184635","article-title":"A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages","volume":"15","author":"Richert","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108294_bib70","article-title":"Multifunctional poly(amino acid) nanomedicine modulates macrophage polarization for osteosarcoma immunotherapy","volume":"391","author":"Sun","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2026.108294_bib71","first-page":"69","article-title":"Macrophage membrane-coated nanovesicles for dual-targeted drug delivery to inhibit tumor and induce macrophage polarization","volume":"23","author":"Huang","year":"2023","journal-title":"Bioact. Mater."},{"issue":"5981","key":"10.1016\/j.phrs.2026.108294_bib72","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108294_bib73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2022.01.026","article-title":"Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy","volume":"343","author":"Huang","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2026.108294_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125479","article-title":"Hybrid membranes-mediated biomimetic-nanoparticle carrying miR-665 for effective tumor treatment by remodeling tumor microenvironment","volume":"675","author":"Zhang","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.phrs.2026.108294_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123587","article-title":"A microsphere-vesicle hybrid system for tumor treatment through enhancement of innate and adaptive immune responses","volume":"325","author":"Chen","year":"2026","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib76","doi-asserted-by":"crossref","first-page":"9405","DOI":"10.1038\/s41467-024-53646-y","article-title":"Tumor-targeted glutathione oxidation catalysis with ruthenium nanoreactors against hypoxic osteosarcoma","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib77","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1038\/s41467-022-34689-5","article-title":"Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib78","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","article-title":"Genome-Informed Targeted Therapy for Osteosarcoma","volume":"9","author":"Sayles","year":"2019","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.phrs.2026.108294_bib79","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11912-017-0634-1","article-title":"CSF-1R Inhibitor Development: Current Clinical Status","volume":"19","author":"Peyraud","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.phrs.2026.108294_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14293","article-title":"Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging","volume":"8","author":"Cuccarese","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2026.108294_bib81","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nri2356","article-title":"Colony-stimulating factors in inflammation and autoimmunity","volume":"8","author":"Hamilton","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"16","key":"10.1016\/j.phrs.2026.108294_bib82","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: First Approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.phrs.2026.108294_bib83","doi-asserted-by":"crossref","DOI":"10.3892\/or.2026.9050","article-title":"<p>Tumor microenvironment in bone sarcomas: Implications for immunotherapy and emerging therapeutic vulnerabilities (Review)<\/p>.","volume":"55","author":"Li","year":"2026","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-026-04288-5","article-title":"Macrophage-centered immunotherapy for osteosarcoma: mechanisms, repolarization, and translational strategies","volume":"24","author":"Li","year":"2026","journal-title":"World J. Surg. Oncol."},{"issue":"28","key":"10.1016\/j.phrs.2026.108294_bib85","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO-25-00210","article-title":"Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG\/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials","volume":"43","author":"Palmerini","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.phrs.2026.108294_bib86","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-24-0103","article-title":"CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib","volume":"30","author":"Gelderblom","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.phrs.2026.108294_bib87","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.phrs.2026.108294_bib88","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/1535-7163.MCT-19-0903","article-title":"Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2","volume":"19","author":"Maloney","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.phrs.2026.108294_bib89","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.7150\/ijbs.95463","article-title":"Nerve growth factor promote VCAM-1-dependent monocyte adhesion and M2 polarization in osteosarcoma microenvironment: Implications for larotrectinib therapy","volume":"20","author":"Lin","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"22","key":"10.1016\/j.phrs.2026.108294_bib90","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1182\/blood.2020005795","article-title":"MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.108294_bib91","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cellsig.2019.01.006","article-title":"Evolving complexity of MIF signaling","volume":"57","author":"Jankauskas","year":"2019","journal-title":"Cell. Signal."},{"key":"10.1016\/j.phrs.2026.108294_bib92","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2017.06.011","article-title":"Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS\/MAPK pathway","volume":"403","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.phrs.2026.108294_bib93","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.300","article-title":"A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drug resistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF)","volume":"5","author":"Liu","year":"2014","journal-title":"Cell. Death Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.652","article-title":"Destabilization of macrophage migration inhibitory factor by 4-IPP reduces NF-\u03baB\/P-TEFb complex-mediated c-Myb transcription to suppress osteosarcoma tumourigenesis","volume":"12","author":"Zheng","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108294_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115293","article-title":"Inhibition of PERK pathway promotes TAMs M1 polarization and ER stress in Osteosarcoma cells hindering tumor progression","volume":"163","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108294_bib96","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/13543784.9.2.329","article-title":"Transcription therapy for acute promyelocytic leukaemia","volume":"9","author":"Douer","year":"2000","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"10","key":"10.1016\/j.phrs.2026.108294_bib97","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/s41401-019-0262-4","article-title":"Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells","volume":"40","author":"Shao","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.phrs.2026.108294_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2024.100655","article-title":"Using \u03b2-Elemene to reduce stemness and drug resistance in osteosarcoma: A focus on the AKT\/FOXO1 signaling pathway and immune modulation","volume":"50","author":"Zhang","year":"2025","journal-title":"J. Bone Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib99","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12263-025-00771-y","article-title":"Arjunolic acid inhibits Wnt3a-mediated macrophage M2 polarization to suppress osteosarcoma progression","volume":"20","author":"Li","year":"2025","journal-title":"Genes. Nutr."},{"issue":"Pt 3","key":"10.1016\/j.phrs.2026.108294_bib100","article-title":"Structural characteristics of a fructan-type polysaccharide from Asparagus cochinchinensis rhizome and its anti-osteosarcoma activity mediated via macrophage polarization","volume":"330","author":"Xia","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib101","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/13880209.2022.2109688","article-title":"Asiaticoside reverses M2 phenotype macrophage polarization-evoked osteosarcoma cell malignant behaviour by TRAF6\/NF-\u03baB inhibition","volume":"60","author":"Li","year":"2022","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.phrs.2026.108294_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2017.06.037","article-title":"Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt\/ GSK3\u03b2\/cyclin D1 pathway","volume":"210","author":"Wang","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phrs.2026.108294_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jprot.2018.04.025","article-title":"Identification and validation nucleolin as a target of curcumol in nasopharyngeal carcinoma cells","volume":"182","author":"Wang","year":"2018","journal-title":"J. Proteom."},{"issue":"14","key":"10.1016\/j.phrs.2026.108294_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27144345","article-title":"Curcumol Synergizes with Cisplatin in Osteosarcoma by Inhibiting M2-like Polarization of Tumor-Associated Macrophages","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"issue":"7-8","key":"10.1016\/j.phrs.2026.108294_bib105","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.phymed.2015.05.005","article-title":"Antitumor and antimetastatic actions of xanthoangelol and 4-hydroxyderricin isolated from Angelica keiskei roots through the inhibited activation and differentiation of M2 macrophages","volume":"22","author":"Sumiyoshi","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phrs.2026.108294_bib106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2014.10.048","article-title":"Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and\/or G1 arrest in tumor cells","volume":"746","author":"Kimura","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108294_bib107","first-page":"14","article-title":"Wrecking neutrophil extracellular traps and antagonizing cancer-associated neurotransmitters by interpenetrating network hydrogels prevent postsurgical cancer relapse and metastases","volume":"39","author":"Zhou","year":"2024","journal-title":"Bioact. Mater."},{"issue":"11","key":"10.1016\/j.phrs.2026.108294_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202307796","article-title":"Endogenous Zinc-Ion-Triggered In Situ Gelation Enables Zn Capture to Reprogram Benign Hyperplastic Prostate Microenvironment and Shrink Prostate","volume":"36","author":"Ge","year":"2024","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib109","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1038\/s41467-025-61135-z","article-title":"Multiplexed self-adaptable Janus hydrogels rescue epithelial malfunction to promote complete trachea repair","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib110","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/s41467-025-62851-2","article-title":"Dynamically urethra-adapted and obligations-oriented trilayer hydrogels integrate scarless urethral repair","volume":"16","author":"Yang","year":"2025","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.phrs.2026.108294_bib111","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrc3838","article-title":"Translational biology of osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"27","key":"10.1016\/j.phrs.2026.108294_bib112","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: Current Treatment and a Collaborative Pathway to Success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"49","key":"10.1016\/j.phrs.2026.108294_bib113","doi-asserted-by":"crossref","first-page":"67424","DOI":"10.1021\/acsami.4c16287","article-title":"Controllable All-in-One Biomimetic Hollow Nanoscaffold Initiating Pyroptosis-Mediated Antiosteosarcoma Targeted Therapy and Bone Defect Repair","volume":"16","author":"Ma","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"27","key":"10.1016\/j.phrs.2026.108294_bib114","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1016\/j.biomaterials.2005.02.002","article-title":"Porosity of 3D biomaterial scaffolds and osteogenesis","volume":"26","author":"Karageorgiou","year":"2005","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1166\/jnn.2014.9127","article-title":"Scaffold design for bone regeneration","volume":"14","author":"Polo-Corrales","year":"2014","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.phrs.2026.108294_bib116","first-page":"361","article-title":"Continuously released Zn(2+) in 3D-printed PLGA\/\u03b2-TCP\/Zn scaffolds for bone defect repair by improving osteoinductive and anti-inflammatory properties","volume":"24","author":"Li","year":"2023","journal-title":"Bioact. Mater."},{"issue":"6","key":"10.1016\/j.phrs.2026.108294_bib117","article-title":"Enhanced Corrosion Resistance and Mechanical Durability of the Composite PLGA\/CaP\/Ti Scaffolds for Orthopedic Implants","volume":"16","author":"Prosolov","year":"2024","journal-title":"Polym. (Basel)"},{"issue":"2","key":"10.1016\/j.phrs.2026.108294_bib118","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/ad1b20","article-title":"Development of hybrid 3D printing approach for fabrication of high-strength hydroxyapatite bioscaffold using FDM and DLP techniques","volume":"16","author":"Cheng","year":"2024","journal-title":"Biofabrication"},{"issue":"5","key":"10.1016\/j.phrs.2026.108294_bib119","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0142-9612(95)98860-G","article-title":"Hydroxyapatite-alumina composites and bone-bonding","volume":"16","author":"Li","year":"1995","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.phrs.2026.108294_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122643","article-title":"Assessment of 3D-Printed Polycaprolactone, Hydroxyapatite Nanoparticles and Diacrylate Poly(ethylene glycol) Scaffolds for Bone Regeneration","volume":"14","author":"Sousa","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2026.108294_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123917","article-title":"Osteosarcoma-on-a-chip model mimicking intra-tumoral heterogeneity to interrogate tumor-associated macrophage reprogramming for immunotherapeutics","volume":"329","author":"Jaiswal","year":"2026","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.phrs.2026.108294_bib122","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.tibs.2022.09.005","article-title":"Recent and future perspectives on engineering interferons and other cytokines as therapeutics","volume":"48","author":"Aung","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2026.108294_bib123","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bios.2016.01.020","article-title":"Recent advances in cytokine detection by immunosensing","volume":"79","author":"Liu","year":"2016","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.phrs.2026.108294_bib124","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jbiotec.2016.10.022","article-title":"Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation","volume":"240","author":"Razaghi","year":"2016","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.phrs.2026.108294_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-026-10152-9","article-title":"Spatial transcriptomic mapping of canine osteosarcoma reveals immune microenvironment features linked to survival","author":"Nance-Richey","year":"2026","journal-title":"Commun. Biol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108294_bib126","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41592-024-02408-1","article-title":"Mapping cellular interactions from spatially resolved transcriptomics data","volume":"21","author":"Zhu","year":"2024","journal-title":"Nat. Methods"},{"issue":"12","key":"10.1016\/j.phrs.2026.108294_bib127","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1158\/0008-5472.CAN-24-3723","article-title":"Spatial Profiling Identifies Regionally Distinct Microenvironments and Targetable Immunosuppressive Mechanisms in Pediatric Osteosarcoma Pulmonary Metastases","volume":"85","author":"Eigenbrood","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108294_bib128","article-title":"A catalase-powered self-oxygen-generating soft nanomotor for photodynamic therapy of osteosarcoma","volume":"32","author":"Tan","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.phrs.2026.108294_bib129","first-page":"77","article-title":"Hydrogel delivering antifibrotic agent and nano-sonosensitizer enhances efficacy of sonodynamic therapy in osteosarcoma treatment","volume":"56","author":"Lin","year":"2026","journal-title":"Bioact. Mater."},{"issue":"21","key":"10.1016\/j.phrs.2026.108294_bib130","doi-asserted-by":"crossref","first-page":"19901","DOI":"10.1021\/acsnano.5c02846","article-title":"Multimodal Regulation of Dendritic Cells via Mineralized Vaccines for Postsurgical Tumor Relapse Prevention","volume":"19","author":"Gu","year":"2025","journal-title":"ACS Nano"},{"issue":"46","key":"10.1016\/j.phrs.2026.108294_bib131","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13","key":"10.1016\/j.phrs.2026.108294_bib132","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-19-0081","article-title":"Mobilization of CD8(+) T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer","volume":"25","author":"Seo","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108294_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1802194","article-title":"Immune exclusion as a recurrent immune-escape state driving treatment resistance in osteosarcoma: insights from single-cell, spatial, and multi-omics studies","volume":"17","author":"Zeng","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108294_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1680554","article-title":"Integrated multi-omics reveals GABARAP-mediated mitophagy and pyruvate metabolism as key drivers of osteosarcoma progression","volume":"16","author":"Han","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108294_bib135","doi-asserted-by":"crossref","DOI":"10.1177\/15330338251336275","article-title":"Multi-omics Analysis of Histone-related Genes in Osteosarcoma: A Multidimensional Integrated Study Revealing Drug Sensitivity and Immune Microenvironment Characteristics","volume":"24","author":"Yang","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib136","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12967-025-07564-2","article-title":"Long non-coding RNAs in osteosarcoma: multifaceted regulators of malignancy and therapeutic resistance","volume":"24","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108294_bib137","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.7150\/jca.104855","article-title":"Identification of M2 macrophage markers for predicting outcome and therapeutic response in osteosarcoma: Integrated analysis of single-cell and bulk RNA-sequencing","volume":"16","author":"Liu","year":"2025","journal-title":"J. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2026.108294_bib138","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011319","article-title":"Malevolent alliance of MYBL2(hi) cancer stem cell and SPP1+ macrophage confers resistance to neoadjuvant immunotherapy in bladder cancer","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib139","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-025-62132-y","article-title":"Metabolism archetype cancer cells induce protumor TREM2(+) macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma","volume":"16","author":"Chu","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib140","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/s41467-024-49916-4","article-title":"Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome","volume":"15","author":"Guimar\u00e3es","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2026.108294_bib141","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","article-title":"Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer","volume":"185","author":"Nalio Ramos","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108294_bib142","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/3677789","article-title":"TREM2 as a Prognostic Biomarker for Osteosarcoma Microenvironment Remodeling","volume":"2023","author":"Shen","year":"2023","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib143","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/0008-5472.CAN-2522-2","article-title":"HER-2\/neu-mediated regulation of components of the MHC class I antigen-processing pathway","volume":"64","author":"Herrmann","year":"2004","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108294_bib144","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/jcb.24022","article-title":"PA28\u03b2 regulates cell invasion of gastric cancer via modulating the expression of chloride intracellular channel 1","volume":"113","author":"Zheng","year":"2012","journal-title":"J. Cell. Biochem."},{"issue":"10","key":"10.1016\/j.phrs.2026.108294_bib145","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317719780","article-title":"Identification of PA28\u03b2 as a potential novel biomarker in human esophageal squamous cell carcinoma","volume":"39","author":"Chen","year":"2017","journal-title":"Tumour Biol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108294_bib146","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00432-010-0778-y","article-title":"Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis","volume":"136","author":"Huang","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108294_bib147","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.7150\/ijbs.90226","article-title":"PSME2 offers value as a biomarker of M1 macrophage infiltration in pan-cancer and inhibits osteosarcoma malignant phenotypes","volume":"20","author":"Li","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2026.108294_bib148","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1750","article-title":"Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities","volume":"14","author":"Chen","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"11","key":"10.1016\/j.phrs.2026.108294_bib149","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.7150\/thno.55986","article-title":"Role of serotonin receptor signaling in cancer cells and anti-tumor immunity","volume":"11","author":"Karmakar","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2026.108294_bib150","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.93174","article-title":"Mapping the molecular motions of 5-HT(3) serotonin-gated channel by voltage-clamp fluorometry","volume":"12","author":"Peverini","year":"2024","journal-title":"Elife"},{"issue":"24","key":"10.1016\/j.phrs.2026.108294_bib151","doi-asserted-by":"crossref","first-page":"11006","DOI":"10.1021\/acs.jmedchem.6b01183","article-title":"Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT(2B)\/5HT(2C) Serotonin Receptor Antagonists","volume":"59","author":"Tosh","year":"2016","journal-title":"J. Med. Chem."},{"issue":"29","key":"10.1016\/j.phrs.2026.108294_bib152","article-title":"Activation of HTR2B Suppresses Osteosarcoma Progression through the STAT1-NLRP3 Inflammasome Pathway and Promotes OASL1+ Macrophage Production to Enhance Antitumor Immunity","volume":"12","author":"Huang","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.phrs.2026.108294_bib153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.12.023","article-title":"Osteosarcoma exocytosis of soluble LGALS3BP mediates macrophages toward a tumoricidal phenotype","volume":"528","author":"Li","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2026.108294_bib154","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.biopha.2016.12.121","article-title":"MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor","volume":"87","author":"Liu","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.phrs.2026.108294_bib155","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/pbc.24686","article-title":"Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments","volume":"61","author":"Anderson","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"issue":"22","key":"10.1016\/j.phrs.2026.108294_bib156","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1002\/cncr.24566","article-title":"Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group","volume":"115","author":"Chou","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108294_bib157","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108294_bib158","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2005.06.031","article-title":"Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and\/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate","volume":"23","author":"Meyers","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108294_bib159","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025877","article-title":"Sarcome-13\/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma","volume":"9","author":"Brard","year":"2019","journal-title":"BMJ Open."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-9966-33-27","article-title":"Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-\u03b3","volume":"33","author":"Pahl","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2026.108294_bib161","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012510","article-title":"Inhibition of osteosarcoma lung metastases by \u03b2-glucan and CD40 agonist is mediated by activation of macrophages and NK cells","volume":"13","author":"Shrestha","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2026.108294_bib162","article-title":"Targeting Macrophage Efferocytosis to Treat Chronic Inflammation in Cancer and Inflammaging","author":"Huang","year":"2026","journal-title":"Aging Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib163","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-025-00750-w","article-title":"Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.phrs.2026.108294_bib164","doi-asserted-by":"crossref","DOI":"10.34133\/research.1193","article-title":"A Bioinspired Approach to Next-Generation Vaccines in Solid Tumors with Engineered Cell Membranes","volume":"9","author":"Zhang","year":"2026","journal-title":"Research"},{"issue":"1","key":"10.1016\/j.phrs.2026.108294_bib165","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01633-7","article-title":"vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. & Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:09:44Z","timestamp":1785074984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":165,"alternative-id":["S1043661826002094"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108294","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting tumor\u2011associated macrophages in osteosarcoma: From molecular reprogramming to immuno-regenerative scaffolds","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108294"}}